Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species

CCT241736 is a dual fms-like tyrosine kinase 3 (FLT3)/Aurora kinase inhibitor in development for the treatment of acute myeloid leukaemia. The successful development of any new drug relies on adequate safety testing including preclinical toxicology studies. Selection of an appropriate preclinical sp...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Eur J Pharm Sci
Glavni autori: Wood, Francesca L., Shepherd, Sam, Hayes, Angela, Liu, Manjuan, Grira, Katia, Mok, Yi, Atrash, Butrus, Faisal, Amir, Bavetsias, Vassilios, Linardopoulos, Spiros, Blagg, Julian, Raynaud, Florence I.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier Science B.V 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6892276/
https://ncbi.nlm.nih.gov/pubmed/30953752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejps.2019.04.004
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items